Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$10.8 million.

  • Cardiff Oncology's Cash from Operations fell 361.51% to -$10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.2 million, marking a year-over-year decrease of 2215.54%. This contributed to the annual value of -$37.7 million for FY2024, which is 2203.52% down from last year.
  • Latest data reveals that Cardiff Oncology reported Cash from Operations of -$10.8 million as of Q3 2025, which was down 361.51% from -$8.3 million recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's Cash from Operations registered a high of -$4.3 million during Q2 2021, and its lowest value of -$12.8 million during Q1 2025.
  • In the last 5 years, Cardiff Oncology's Cash from Operations had a median value of -$8.0 million in 2023 and averaged -$8.3 million.
  • In the last 5 years, Cardiff Oncology's Cash from Operations tumbled by 7439.24% in 2021 and then soared by 2397.23% in 2023.
  • Over the past 5 years, Cardiff Oncology's Cash from Operations (Quarter) stood at -$7.4 million in 2021, then fell by 27.06% to -$9.4 million in 2022, then grew by 23.97% to -$7.1 million in 2023, then crashed by 43.82% to -$10.3 million in 2024, then dropped by 5.52% to -$10.8 million in 2025.
  • Its last three reported values are -$10.8 million in Q3 2025, -$8.3 million for Q2 2025, and -$12.8 million during Q1 2025.